Impact of Genetic Variation in Adrenergic Receptors on β-Blocker Effectiveness and Safety in Cardiovascular Disease Management: A Systematic Review

<b>Background/Objectives:</b> A systematic review was conducted to compile all the evidence on the impact of <i>ADRB1</i> and <i>ADRB2</i> genetic variants on the response to β-blockers, used for the management of cardiovascular diseases. <b>Methods:</b&g...

Full description

Saved in:
Bibliographic Details
Main Authors: Houwaida Abbes, Paula Soria-Chacartegui, Asma Omezzine, Francisco Abad-Santos, Pablo Zubiaur
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Pharmaceuticals
Subjects:
Online Access:https://www.mdpi.com/1424-8247/18/4/493
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850180026010435584
author Houwaida Abbes
Paula Soria-Chacartegui
Asma Omezzine
Francisco Abad-Santos
Pablo Zubiaur
author_facet Houwaida Abbes
Paula Soria-Chacartegui
Asma Omezzine
Francisco Abad-Santos
Pablo Zubiaur
author_sort Houwaida Abbes
collection DOAJ
description <b>Background/Objectives:</b> A systematic review was conducted to compile all the evidence on the impact of <i>ADRB1</i> and <i>ADRB2</i> genetic variants on the response to β-blockers, used for the management of cardiovascular diseases. <b>Methods:</b> After searching in PubMed, PharmGKB, and the Cochrane Central Register of Controlled Trials including terms related to these drugs, genes, and pathologies, 1182 articles were retrieved, 29 of which met the inclusion criteria. A β-adrenoreceptor (ADRB) blockade qualitative variable was inferred for all the associations between genetic variants and clinical phenotypes. <b>Results:</b> The relationship between <i>ADRB1</i> rs1801253 (G>C) C allele and higher receptor blockade showed a moderate overall level of evidence, reaching a high level on its relationship with higher reduction in the systolic (SBP) and diastolic blood pressure and heart rate (HR). The relationship between <i>ADRB1</i> rs1801252 (A>G) G allele and lower receptor blockade reached an overall high level of evidence, considering its impact on the reduction in the SBP, HR, left ventricular end-diastolic diameter, and incidence of major cardiovascular events. The relationship between <i>ADRB2</i> rs1042714 (G>C) C allele and lower receptor blockade reached a moderate overall level of evidence due to its impact on HR, pulmonary wedge pressure, and left ventricular ejection fraction response. The <i>ADRB2</i> rs1042713 (G>A) A allele was associated with higher receptor blockade and higher HR reduction with a low level of evidence. <b>Conclusions:</b> The genotyping of both <i>ADRB1</i> variants may be clinically useful; further investigation is required on the relevance of both <i>ADRB2</i> variants. Further research is warranted to determine the clinical usefulness of <i>ADRB</i> preemptive genotyping.
format Article
id doaj-art-215c2f3a96fc41a5978dbf24e03785e7
institution OA Journals
issn 1424-8247
language English
publishDate 2025-03-01
publisher MDPI AG
record_format Article
series Pharmaceuticals
spelling doaj-art-215c2f3a96fc41a5978dbf24e03785e72025-08-20T02:18:20ZengMDPI AGPharmaceuticals1424-82472025-03-0118449310.3390/ph18040493Impact of Genetic Variation in Adrenergic Receptors on β-Blocker Effectiveness and Safety in Cardiovascular Disease Management: A Systematic ReviewHouwaida Abbes0Paula Soria-Chacartegui1Asma Omezzine2Francisco Abad-Santos3Pablo Zubiaur4Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa (IP), Universidad Autónoma de Madrid (UAM), 28049 Madrid, SpainClinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa (IP), Universidad Autónoma de Madrid (UAM), 28049 Madrid, SpainBiochemistry Department, LR12SP11, Sahloul University Hospital, Sousse 4054, TunisiaClinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa (IP), Universidad Autónoma de Madrid (UAM), 28049 Madrid, SpainClinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa (IP), Universidad Autónoma de Madrid (UAM), 28049 Madrid, Spain<b>Background/Objectives:</b> A systematic review was conducted to compile all the evidence on the impact of <i>ADRB1</i> and <i>ADRB2</i> genetic variants on the response to β-blockers, used for the management of cardiovascular diseases. <b>Methods:</b> After searching in PubMed, PharmGKB, and the Cochrane Central Register of Controlled Trials including terms related to these drugs, genes, and pathologies, 1182 articles were retrieved, 29 of which met the inclusion criteria. A β-adrenoreceptor (ADRB) blockade qualitative variable was inferred for all the associations between genetic variants and clinical phenotypes. <b>Results:</b> The relationship between <i>ADRB1</i> rs1801253 (G>C) C allele and higher receptor blockade showed a moderate overall level of evidence, reaching a high level on its relationship with higher reduction in the systolic (SBP) and diastolic blood pressure and heart rate (HR). The relationship between <i>ADRB1</i> rs1801252 (A>G) G allele and lower receptor blockade reached an overall high level of evidence, considering its impact on the reduction in the SBP, HR, left ventricular end-diastolic diameter, and incidence of major cardiovascular events. The relationship between <i>ADRB2</i> rs1042714 (G>C) C allele and lower receptor blockade reached a moderate overall level of evidence due to its impact on HR, pulmonary wedge pressure, and left ventricular ejection fraction response. The <i>ADRB2</i> rs1042713 (G>A) A allele was associated with higher receptor blockade and higher HR reduction with a low level of evidence. <b>Conclusions:</b> The genotyping of both <i>ADRB1</i> variants may be clinically useful; further investigation is required on the relevance of both <i>ADRB2</i> variants. Further research is warranted to determine the clinical usefulness of <i>ADRB</i> preemptive genotyping.https://www.mdpi.com/1424-8247/18/4/493β-blockeradrenergic receptors<i>ADRB1</i><i>ADRB2</i>genetic variantblockade
spellingShingle Houwaida Abbes
Paula Soria-Chacartegui
Asma Omezzine
Francisco Abad-Santos
Pablo Zubiaur
Impact of Genetic Variation in Adrenergic Receptors on β-Blocker Effectiveness and Safety in Cardiovascular Disease Management: A Systematic Review
Pharmaceuticals
β-blocker
adrenergic receptors
<i>ADRB1</i>
<i>ADRB2</i>
genetic variant
blockade
title Impact of Genetic Variation in Adrenergic Receptors on β-Blocker Effectiveness and Safety in Cardiovascular Disease Management: A Systematic Review
title_full Impact of Genetic Variation in Adrenergic Receptors on β-Blocker Effectiveness and Safety in Cardiovascular Disease Management: A Systematic Review
title_fullStr Impact of Genetic Variation in Adrenergic Receptors on β-Blocker Effectiveness and Safety in Cardiovascular Disease Management: A Systematic Review
title_full_unstemmed Impact of Genetic Variation in Adrenergic Receptors on β-Blocker Effectiveness and Safety in Cardiovascular Disease Management: A Systematic Review
title_short Impact of Genetic Variation in Adrenergic Receptors on β-Blocker Effectiveness and Safety in Cardiovascular Disease Management: A Systematic Review
title_sort impact of genetic variation in adrenergic receptors on β blocker effectiveness and safety in cardiovascular disease management a systematic review
topic β-blocker
adrenergic receptors
<i>ADRB1</i>
<i>ADRB2</i>
genetic variant
blockade
url https://www.mdpi.com/1424-8247/18/4/493
work_keys_str_mv AT houwaidaabbes impactofgeneticvariationinadrenergicreceptorsonbblockereffectivenessandsafetyincardiovasculardiseasemanagementasystematicreview
AT paulasoriachacartegui impactofgeneticvariationinadrenergicreceptorsonbblockereffectivenessandsafetyincardiovasculardiseasemanagementasystematicreview
AT asmaomezzine impactofgeneticvariationinadrenergicreceptorsonbblockereffectivenessandsafetyincardiovasculardiseasemanagementasystematicreview
AT franciscoabadsantos impactofgeneticvariationinadrenergicreceptorsonbblockereffectivenessandsafetyincardiovasculardiseasemanagementasystematicreview
AT pablozubiaur impactofgeneticvariationinadrenergicreceptorsonbblockereffectivenessandsafetyincardiovasculardiseasemanagementasystematicreview